196 related articles for article (PubMed ID: 29552859)
41. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
42. [Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells].
Li BJ; Liu TB; Wang WF; Lin MH; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):1-7. PubMed ID: 26913384
[TBL] [Abstract][Full Text] [Related]
43. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
44. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
[TBL] [Abstract][Full Text] [Related]
46. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
[TBL] [Abstract][Full Text] [Related]
47. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
48. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
49. [Anti-Leukemia Effect and Mechanism of Oridonin on Imatinib-Sensitive and Imatinib-Resistant K562 Cells].
Shan QQ; Guo Y; Gong YP; Lin J; Wang YS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1378-1383. PubMed ID: 29070111
[TBL] [Abstract][Full Text] [Related]
50. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
Yuan R; Chang J; He J
Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790
[TBL] [Abstract][Full Text] [Related]
51. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
52. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
53. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
54. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
Zhou Q; Chen Y; Chen X; Zhao W; Zhong Y; Wang R; Jin M; Qiu Y; Kong D
Int J Biol Sci; 2016; 12(6):631-8. PubMed ID: 27194941
[TBL] [Abstract][Full Text] [Related]
55. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
56. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
57. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
58. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
59. Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
Cai H; He X; Yang C
Phytother Res; 2018 Sep; 32(9):1764-1769. PubMed ID: 29701267
[TBL] [Abstract][Full Text] [Related]
60. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
